Zydus Lifesciences receives USFDA approval to produce prostrate cancer drug ...Middle East

Business Standard - Economy
Zydus Lifesciences receives USFDA approval to produce prostrate cancer drug
Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to produce a generic prostate cancer treatment drug. The company has received tentative approval from the US Food and Drug Administration (USFDA) to manufacture Enzalutamide tablets (40 mg and 80 mg), the drug maker said in a regulatory filing. Enzalutamide tablets are androgen receptor inhibitors indicated for the treatment of patients with castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. The product would be manufactured at the Group's manufacturing site at SEZ, Ahmedabad. As per IQVIA MAT July 2024 data, Enzalutamide tablets (40 mg and 80 mg) had annual sales

Hence then, the article about zydus lifesciences receives usfda approval to produce prostrate cancer drug was published today ( ) and is available on Business Standard ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Zydus Lifesciences receives USFDA approval to produce prostrate cancer drug )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in Economy


Latest News